Trials / Completed
CompletedNCT02627144
Bevacizumab in Metastatic Renal Cancer
AVASTIN® First Line in Metastatic Renal Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 365 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression. |
| DRUG | Interferon alpha-2a | Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression. |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2015-12-10
- Last updated
- 2016-08-29
- Results posted
- 2016-07-12
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02627144. Inclusion in this directory is not an endorsement.